LBA
DNLI icon

Letko, Brosseau & Associates’s Denali Therapeutics DNLI Stock Holding History

Letko, Brosseau & Associates’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$202K Buy
+7,850
New +$161K ﹤0.01% 104
2024
Q4 		– Sell
-11,350
Closed -$331K – 102
2024
Q3 		$331K Hold
11,350
– – 0.01% 89
2024
Q2 		$264K Buy
+11,350
New +$218K 0.01% 92

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Letko, Brosseau & Associates's DNLI Position: Q2 2026 in Review

Letko, Brosseau & Associates opened a new position in Denali Therapeutics (DNLI) in Q2 2026: 7,850 shares worth $202K. The stake represents ﹤0.01% of the portfolio and ranks #104 among its holdings. This is a return to the name: Letko, Brosseau & Associates previously reported a position in DNLI as recently as Q3 2024.

Letko, Brosseau & Associates first reported a position in DNLI in Q2 2024 and has held it in 3 quarters since. The position peaked at $331K in Q3 2024. 293 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • Letko, Brosseau & Associates held 7,850 shares of Denali Therapeutics worth $202K as of Q2 2026.
  • Denali Therapeutics was a new Letko, Brosseau & Associates position in Q2 2026.
  • Denali Therapeutics made up ﹤0.01% of Letko, Brosseau & Associates's portfolio in Q2 2026, its #104 holding.
  • Letko, Brosseau & Associates first reported a position in Denali Therapeutics in Q2 2024 and has held it in 3 quarters since.
  • Letko, Brosseau & Associates's Denali Therapeutics position peaked at $331K in Q3 2024.
  • 293 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Letko, Brosseau & Associates's 13F filing for Q2 2026, filed 13 Aug 2026.